In the news

December 14, 2022

Comparative oncology research center at Purdue to be named for Evan and Sue Ann Werling

The Purdue University Board of Trustees has approved the naming of the Evan and Sue Ann Werling Comparative Oncology Research Center in recognition of the donors’ $10 million gift. The center, part of the College of Veterinary Medicine, will partner with the Purdue Center for Cancer Research (PCCR) to advance cancer research benefiting pets and humans.

November 21, 2022

Man’s best friend leads the way to early cancer detection

A canine cancer scientist at Purdue University’s College of Veterinary Medicine is working to take the first steps to make a serious form of cancer in dogs — one with analogues to human health — easier to detect and treat before it has become more advanced.

November 7, 2022

Affordable cervical cancer test holds life-preserving promise

Purdue researchers Jacqueline Linnes and Sulma Mohammed are determined to save lives by developing a low-cost, point-of-care paper test that could revolutionize cervical cancer detection worldwide.

November 1, 2022

Improving prostate cancer relapse forecast by 14 months

A new tool could help save lives by predicting prostate cancer relapse 14 months earlier than current standard methods.

October 5, 2022

Your support matters!

Thanks to you, in just one year, three new Purdue drugs were FDA-approved and already are helping cancer patients.

September 8, 2022

Anvil used to train cancer researchers in big data analysis

Purdue’s powerful Anvil supercomputer is being used to train a group of cancer researchers – from graduate students to professors and practicing physicians – on big data management, analysis and visualization skills.

August 31, 2022

Mesecar named interim director of Purdue Center for Cancer Research

Andrew Mesecar, the Walther Professor in Cancer Structural Biology, will serve as the interim director of the Purdue Center for Cancer Research (PCCR) during the current national search for a permanent leader.

New patent-pending method mass-produces antitumor cells to treat blood diseases and cancer

A Purdue University chemical engineer has improved upon traditional methods to produce off-the-shelf human immune cells that show strong antitumor activity, according to a paper published in the peer-reviewed journal Cell Reports.

Surprise $8.5 million estate gift will fund more than 40 years of cancer research

Thanks to an unexpected bequest of $8.5 million from fellow faculty member John Capaldi, Philip Low, Purdue University’s Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry, has funding to support more than 40 years’ worth of cancer research.

Purdue University research instrumental in early development of FDA-approved advanced prostate cancer diagnostic and treatment

A new precision treatment that offers hope for patients with advanced prostate cancer has been granted approval by the U.S. Food and Drug Administration.